DURECT CorpNASDAQ:DRRX
- LAST PRICE0.9399
- TODAY'S CHANGE (%)0.0274 (3.0027%)
- Bid / Lots0.9399/ 1
- Ask / Lots0.9400/ 26
- Open / Previous Close0.9325 / 0.9125
- Day Range
- 52 Week Range
- Volume950
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DRRX |
|---|---|---|
| 09:32 ET | 927 | 0.9399 |
Nov 25, 2024
DURECT Corporation Announces Sale of ALZET(R) Product Line to Lafayette Instrument Co. for $17.5 Million, from 6:00AM ET on Monday Nov 25, 2024 by Dow Jones
6:00AM ET on Monday Nov 25, 2024 by Dow Jones
Nov 13, 2024
*DJ Durect 3Q Loss/Shr 14c >DRRX, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 13, 2024 by Dow JonesDURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 6, 2024
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update, from 4:45PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:45PM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
DURECT Corp | 28.3M | -1.7x | --- |
Bolt Biotherapeutics Inc | 24.1M | -0.4x | --- |
Pulmatrix Inc | 26.8M | -2.9x | --- |
Tonix Pharmaceuticals Holding Corp | 35.2M | 0.0x | --- |
Spruce Biosciences Inc | 22.6M | -0.6x | --- |
Curis Inc | 37.7M | -0.6x | --- |
Company Information
DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. It also completed Alcohol-Associated Hepatitis (AHFIRM) Phase 2b study.
Contact Information
- Headquarters
- 10240 Bubb RoadCUPERTINO, CA, United States 95014
- Phone
- 408-777-1417
- Fax
- 408-777-3577
Executives
- Independent Chairman of the Board
- Gail Maderis
- President, Chief Executive Officer, Director
- James Brown
- Chief Financial Officer, Company Secretary
- Timothy Papp
- Chief Medical Officer
- Norman Sussman
- Independent Director
- Mohammad Azab
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $28.3M |
|---|---|
Revenue (TTM) | $8.6M |
Shares Outstanding | 31.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $-0.56 |
Book Value | $0.49 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | 3.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -225.06% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
